BCR and diffuse large B-cell lymphoma: A major advance in DLBCL therapy development can be achieved with the advent of ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor (BCR) dependent NF-kB activation and is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma and Waldenström’s macroglobulinemia [10, 11].